CA2949994A1 - Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus - Google Patents
Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus Download PDFInfo
- Publication number
- CA2949994A1 CA2949994A1 CA2949994A CA2949994A CA2949994A1 CA 2949994 A1 CA2949994 A1 CA 2949994A1 CA 2949994 A CA2949994 A CA 2949994A CA 2949994 A CA2949994 A CA 2949994A CA 2949994 A1 CA2949994 A1 CA 2949994A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- protein
- sequence seq
- substantially pure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 216
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 216
- 239000000203 mixture Substances 0.000 title claims description 5
- 241000700721 Hepatitis B virus Species 0.000 title abstract description 4
- 210000004698 lymphocyte Anatomy 0.000 title description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 186
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 61
- 239000011886 peripheral blood Substances 0.000 claims abstract description 61
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 52
- 210000002540 macrophage Anatomy 0.000 claims abstract description 39
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 35
- 210000002381 plasma Anatomy 0.000 claims abstract description 34
- 230000001105 regulatory effect Effects 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims abstract description 9
- 102100033467 L-selectin Human genes 0.000 claims abstract description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract 4
- 241000282414 Homo sapiens Species 0.000 claims description 496
- 210000000952 spleen Anatomy 0.000 claims description 84
- 230000000694 effects Effects 0.000 claims description 51
- 239000000047 product Substances 0.000 claims description 39
- 208000002672 hepatitis B Diseases 0.000 claims description 26
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 229940060415 hepatitis b immune globulin Drugs 0.000 claims description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000011146 sterile filtration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 239000002031 ethanolic fraction Substances 0.000 claims 4
- 239000000706 filtrate Substances 0.000 claims 4
- 238000007865 diluting Methods 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 108
- 208000015181 infectious disease Diseases 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 210000002865 immune cell Anatomy 0.000 abstract description 8
- 210000000056 organ Anatomy 0.000 abstract description 4
- 210000001165 lymph node Anatomy 0.000 description 76
- 230000027455 binding Effects 0.000 description 67
- 230000001225 therapeutic effect Effects 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 64
- 229940039715 human prothrombin Drugs 0.000 description 64
- 230000001086 cytosolic effect Effects 0.000 description 53
- 108010088751 Albumins Proteins 0.000 description 46
- 102000009027 Albumins Human genes 0.000 description 46
- 230000000069 prophylactic effect Effects 0.000 description 45
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 44
- 230000003828 downregulation Effects 0.000 description 44
- 229940106780 human fibrinogen Drugs 0.000 description 40
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 36
- 210000003289 regulatory T cell Anatomy 0.000 description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 230000003827 upregulation Effects 0.000 description 29
- 102000003886 Glycoproteins Human genes 0.000 description 26
- 108090000288 Glycoproteins Proteins 0.000 description 26
- 230000008569 process Effects 0.000 description 23
- 210000004443 dendritic cell Anatomy 0.000 description 21
- 210000004165 myocardium Anatomy 0.000 description 19
- 210000001616 monocyte Anatomy 0.000 description 18
- 208000035473 Communicable disease Diseases 0.000 description 16
- 238000011321 prophylaxis Methods 0.000 description 16
- 238000012353 t test Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 14
- 210000003071 memory t lymphocyte Anatomy 0.000 description 14
- 230000004060 metabolic process Effects 0.000 description 14
- 230000021953 cytokinesis Effects 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 12
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 210000004544 dc2 Anatomy 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 210000001723 extracellular space Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000017734 multicellular organismal process Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000003436 cytoskeletal effect Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 210000005061 intracellular organelle Anatomy 0.000 description 9
- 101150079748 MCM8 gene Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 108091060290 Chromatid Proteins 0.000 description 7
- 101100407318 Xenopus laevis pds5a-a gene Proteins 0.000 description 7
- 210000004756 chromatid Anatomy 0.000 description 7
- 101150109441 pds5 gene Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000033077 cellular process Effects 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000003632 microfilament Anatomy 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000033210 regulation of biological quality Effects 0.000 description 6
- 230000025969 response to chemical stimulus Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 description 5
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 230000021592 metal ion homeostasis Effects 0.000 description 5
- 230000003938 response to stress Effects 0.000 description 5
- 230000026676 system process Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 210000003956 transport vesicle Anatomy 0.000 description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 101150011967 Mthfsd gene Proteins 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 101100537444 Xenopus laevis tmem267 gene Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000010212 intracellular staining Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 230000025366 tissue development Effects 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- 102000057234 Acyl transferases Human genes 0.000 description 3
- 108700016155 Acyl transferases Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 108091007403 Cholesterol transporters Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 3
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000031154 cholesterol homeostasis Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000015862 eukaryotic cell surface binding Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012667 heterotypic cell-cell adhesion Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000008604 lipoprotein metabolism Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000033087 muscle system process Effects 0.000 description 3
- 210000003365 myofibril Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000005305 organ development Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000012006 phospholipid homeostasis Effects 0.000 description 3
- 230000019525 primary metabolic process Effects 0.000 description 3
- 230000006318 protein oxidation Effects 0.000 description 3
- 230000029983 protein stabilization Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000012121 regulation of immune response Effects 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 102000040811 transporter activity Human genes 0.000 description 3
- 230000008601 triglyceride homeostasis Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102100021238 Dynamin-2 Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 101800000460 Protein TF Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000023837 negative regulation of proteolysis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000011363 regulation of cellular process Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000033772 system development Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010043137 Actomyosin Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100205030 Caenorhabditis elegans hars-1 gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102100033482 Enolase-phosphatase E1 Human genes 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000850450 Homo sapiens Enolase-phosphatase E1 Proteins 0.000 description 1
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 101100082091 Mus musculus Pacrgl gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100038843 Neuropeptides B/W receptor type 2 Human genes 0.000 description 1
- 101710150355 Neuropeptides B/W receptor type 2 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101710134436 Putative uncharacterized protein Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000004613 cellular response to starvation Effects 0.000 description 1
- 230000012018 cellular response to stimulus Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000005219 defense response to fungus Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000441 effect on granulocytes Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003878 glomerular mesangial cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940036107 hepatitis b immunoglobulin Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000016506 interphase of mitotic cell cycle Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000016557 multi-organism process Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008212 organismal development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000020964 regulation of blood coagulation Effects 0.000 description 1
- 230000031931 regulation of body fluid levels Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004005 regulation of localization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007109 response to nutrient levels Effects 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 230000008399 response to wounding Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003664P | 2014-05-28 | 2014-05-28 | |
| US62/003,664 | 2014-05-28 | ||
| PCT/US2015/032807 WO2015184050A1 (en) | 2014-05-28 | 2015-05-28 | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2949994A1 true CA2949994A1 (en) | 2015-12-03 |
Family
ID=54699755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2949994A Pending CA2949994A1 (en) | 2014-05-28 | 2015-05-28 | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3148574B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017525752A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107106664A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015266997A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016027818A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2949994A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2878043T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016015574A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016151761A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015184050A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015184050A1 (en) | 2014-05-28 | 2015-12-03 | Rare Antibody Antigen Supply, Inc. | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus |
| CN107921080A (zh) * | 2015-04-02 | 2018-04-17 | K·黄 | 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法 |
| WO2016161421A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | A method of manufacturing intravenous immunoglobulin from fraction iii |
| CN118878610B (zh) * | 2024-03-19 | 2025-09-02 | 北京达尔文细胞生物科技有限公司 | 一种蛋白聚合物及其生产工艺 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| TWI532498B (zh) * | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| CA2639003A1 (en) * | 2008-08-20 | 2010-02-20 | Canadian Blood Services | Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations |
| EP2556087A1 (en) * | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| KR20130080443A (ko) * | 2010-05-14 | 2013-07-12 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 개선된 보체 수용체 ２(ｃｒ２) 표적 그룹들 |
| WO2015184050A1 (en) | 2014-05-28 | 2015-12-03 | Rare Antibody Antigen Supply, Inc. | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus |
| TW201335181A (zh) * | 2012-01-31 | 2013-09-01 | Kieu Hoang | ５５種新發現的蛋白質之序列及其應用 |
-
2015
- 2015-05-28 WO PCT/US2015/032807 patent/WO2015184050A1/en not_active Ceased
- 2015-05-28 EP EP15799654.7A patent/EP3148574B1/en not_active Revoked
- 2015-05-28 AU AU2015266997A patent/AU2015266997A1/en not_active Abandoned
- 2015-05-28 BR BR112016027818A patent/BR112016027818A2/pt not_active Application Discontinuation
- 2015-05-28 MX MX2016015574A patent/MX2016015574A/es unknown
- 2015-05-28 ES ES15799654T patent/ES2878043T3/es active Active
- 2015-05-28 CA CA2949994A patent/CA2949994A1/en active Pending
- 2015-05-28 RU RU2016151761A patent/RU2016151761A/ru not_active Application Discontinuation
- 2015-05-28 JP JP2017515008A patent/JP2017525752A/ja active Pending
- 2015-05-28 CN CN201580041532.2A patent/CN107106664A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017525752A (ja) | 2017-09-07 |
| CN107106664A (zh) | 2017-08-29 |
| EP3148574B1 (en) | 2021-04-14 |
| AU2015266997A1 (en) | 2016-12-08 |
| RU2016151761A (ru) | 2018-07-03 |
| ES2878043T3 (es) | 2021-11-18 |
| EP3148574A1 (en) | 2017-04-05 |
| BR112016027818A2 (pt) | 2017-10-24 |
| WO2015184050A1 (en) | 2015-12-03 |
| MX2016015574A (es) | 2018-05-28 |
| RU2016151761A3 (cg-RX-API-DMAC7.html) | 2018-12-26 |
| EP3148574A4 (en) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2735139C2 (ru) | Полученные из лизата тромбоцитов человека внеклеточные везикулы для применения в медицине | |
| EP3134120B1 (en) | Compositions and methods for treating cytokine-related disorders | |
| CN105101978A (zh) | Nk细胞强化型血液制剂的制造方法 | |
| JP5847518B2 (ja) | Ｎｋ細胞強化型血液製剤の製造方法 | |
| US20190328792A1 (en) | Mesenchymal stem cell-derived extracellular vesicles and their medical use | |
| WO2012099093A1 (ja) | Nk細胞強化型血液製剤の製造方法 | |
| EP3148574B1 (en) | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus | |
| CN106754723B (zh) | 一种具有抗肿瘤功能的免疫细胞及其应用 | |
| CN111286488B (zh) | 一种自然杀伤细胞体外培养方法 | |
| JP4275680B2 (ja) | リンパ球の活性・増殖に係る培養方法 | |
| CN115120713A (zh) | 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途 | |
| JP2017520582A (ja) | 関節リウマチ治療のための間葉系間質細胞 | |
| JP2022541293A (ja) | がん細胞療法用のｐ２１発現単球 | |
| NZ537382A (en) | Extracorporeal photopheresis in combination with anti-TNF treatment | |
| JP5386083B2 (ja) | 自己免疫疾患および変性疾患を治療する方法 | |
| US20180021376A1 (en) | Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins | |
| JP7762964B2 (ja) | カクテル樹状細胞ワクチンの製造方法 | |
| CN117986351B (zh) | 一种ra自身抗原表位多肽及其制备的抗原特异性t细胞疫苗、制备方法和应用 | |
| US20240200030A1 (en) | Tumor proximal cell collection | |
| Crum | Matrix-Bound Nanovesicles as an Immunomodulatory Therapy for Rheumatoid Arthritis | |
| Gkanatsiou | Identification of immunosuppressive mechanisms in Glioblastoma Mulltiforme brain tumours | |
| Chen et al. | CCR2 Orchestrates Preferential Homing and Therapeutic Efficacy of Gingival Mesenchymal Stem Cell‐Derived Extracellular Vesicles in Rheumatoid Arthritis | |
| CN119923275A (zh) | CD158d分子、其中和抗体，及应用 | |
| CN115305238A (zh) | 一种提高自然杀伤细胞杀伤力的成分在自然杀伤细胞培养中的应用 | |
| CN109402056A (zh) | 靶向kif20a阳性胰腺癌双特异性抗体nk细胞及制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |